Trial Profile

Open-label extension trial of Emestedastat for Alzheimer's disease .

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 08 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Emestedastat (Primary)
Indications Alzheimer's disease; Dementia
Focus Therapeutic Use
Acronyms XanaMIA-DUR

Most Recent Events

08 Jul 2025 New trial record
30 Jun 2025 According to Actinogen Medical media release, The company plans to initiate this trial in Q1 2026 and be open to all former and current participants in the XanaMIA Phase 2b/3 trial.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com